このエントリーをはてなブックマークに追加
ID 53996
JaLCDOI
フルテキストURL
著者
Yasunaka, Tetsuya Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Ikeda, Fusao Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Wada, Nozomu Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Morimoto, Yuki Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Fujioka, Shin-ichi Department of Internal Medicine, Okayama Saiseikai General hospital
Toshimori, Junichi Department of Gastroenterology, Okayama Red Cross Hospital
Kobashi, Haruhiko Department of Gastroenterology, Okayama Red Cross Hospital
Kariyama, Kazuya Department of Liver Disease Center, Okayama City Hospital
Morimoto, Yoichi Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Takayama, Hiroki Department of Gastroenterology, Tsuyama Central Hospital
Seno, Tomonori Department of Hepatology, Kagawa Prefectural Central Hospital
Takaguchi, Koichi Department of Hepatology, Kagawa Prefectural Central Hospital
Moriya, Akio Department of Medicine, Mitoyo Central Hospital
Miyatake, Hirokazu Department of Internal Medicine, Hiroshima City Hospital
Okamoto, Ryoichi Department of Internal Medicine, Hiroshima City Hospital
Yabushita, Kazuhisa Department of Internal Medicine, Fukuyama City Hospital
Takaki, Akinobu Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamamoto, Kazuhide Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録
Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged≥35 years with HBV DNA ≥4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.
キーワード
entecavir
hepatitis B virus
lamivudine
hepatocellular carcinoma
Amo Type
Original Article
発行日
2016-02
出版物タイトル
Acta Medica Okayama
70巻
1号
出版者
Okayama University Medical School
開始ページ
1
終了ページ
12
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT